Eledon Pharmaceuticals Shares Sink After Pricing $50M Public Offering

Dow Jones

2025/11/12

By Connor Hart

Shares of Eledon Pharmaceuticals fell after the company priced a $50 million public offering of common stock and pre-funded warrants.

The stock fell 17% to $1.77 in premarket trading Wednesday. Through Tuesday's close, shares have lost nearly half of their value in the past year.

Ahead of the opening bell, the Irvine, Calif., biotech company said it will sell about 15.2 million shares of its common stock for $1.65 apiece. To certain investors, the company will instead sell pre-funded warrants immediately exercisable to purchase common stock.

Eledon will also grant underwriters a 30-day option to purchase up to about 4.55 million shares of common stock at a discounted price.

The company said it will use net proceeds from the sale to support the clinical development of its product candidates and advance its pipeline programs, as well as for general corporate purposes.

Leerink Partners, Cantor and LifeSci Capital are acting as joint book-running managers for the offering, which is expected to close on or about Thursday.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

November 12, 2025 08:45 ET (13:45 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582374400"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582374400\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582374400?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 21:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582374400","market":"sh","top_or_hot":-1,"title":"Eledon Pharmaceuticals Shares Sink After Pricing $50M Public Offering","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Eledon Pharmaceuticals fell after the company priced a $50 million public offering of common stock and pre-funded warrants. \n</p>\n<p>\n  The stock fell 17% to $1.77 in premarket trading Wednesday. Through Tuesday's close, shares have lost nearly half of their value in the past year. \n</p>\n<p>\n  Ahead of the opening bell, the Irvine, Calif., biotech company said it will sell about 15.2 million shares of its common stock for $1.65 apiece. To certain investors, the company will instead sell pre-funded warrants immediately exercisable to purchase common stock. \n</p>\n<p>\n  Eledon will also grant underwriters a 30-day option to purchase up to about 4.55 million shares of common stock at a discounted price. \n</p>\n<p>\n  The company said it will use net proceeds from the sale to support the clinical development of its product candidates and advance its pipeline programs, as well as for general corporate purposes. \n</p>\n<p>\n  Leerink Partners, Cantor and LifeSci Capital are acting as joint book-running managers for the offering, which is expected to close on or about Thursday. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 12, 2025 08:45 ET (13:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eledon Pharmaceuticals Shares Sink After Pricing $50M Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEledon Pharmaceuticals Shares Sink After Pricing $50M Public Offering\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-11-12 21:45</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Eledon Pharmaceuticals fell after the company priced a $50 million public offering of common stock and pre-funded warrants. \n</p>\n<p>\n  The stock fell 17% to $1.77 in premarket trading Wednesday. Through Tuesday's close, shares have lost nearly half of their value in the past year. \n</p>\n<p>\n  Ahead of the opening bell, the Irvine, Calif., biotech company said it will sell about 15.2 million shares of its common stock for $1.65 apiece. To certain investors, the company will instead sell pre-funded warrants immediately exercisable to purchase common stock. \n</p>\n<p>\n  Eledon will also grant underwriters a 30-day option to purchase up to about 4.55 million shares of common stock at a discounted price. \n</p>\n<p>\n  The company said it will use net proceeds from the sale to support the clinical development of its product candidates and advance its pipeline programs, as well as for general corporate purposes. \n</p>\n<p>\n  Leerink Partners, Cantor and LifeSci Capital are acting as joint book-running managers for the offering, which is expected to close on or about Thursday. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 12, 2025 08:45 ET (13:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ELDN","symbol_name":"Eledon Pharmaceuticals, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2582374400","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582374400","pubTimestamp":1762955100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Eledon Pharmaceuticals fell after the company priced a $50 million public offering of common stock and pre-funded warrants.The stock fell 17% to $1.77 in premarket trading Wednesday. Through Tuesday's close, shares have lost nearly half of their value in the past year.Ahead of the opening bell, the Irvine, Calif., biotech company said it will sell about 15.2 million shares of its common stock for $1.65 apiece. To certain investors, the company will instead sell pre-funded warrants immediately exercisable to purchase common stock.Eledon will also grant underwriters a 30-day option to purchase up to about 4.55 million shares of common stock at a discounted price.The company said it will use net proceeds from the sale to support the clinical development of its product candidates and advance its pipeline programs, as well as for general corporate purposes.Leerink Partners, Cantor and LifeSci Capital are acting as joint book-running managers for the offering, which is expected to ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ELDN":"Eledon Pharmaceuticals, Inc.","BK4139":"生物科技"},"translate_title":"Eledon Pharmaceuticals公开发行5000万美元后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELDN":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Shares of Eledon Pharmaceuticals fell after the company priced a $50 million public offering of common stock and pre-funded warrants. \n\n\n  The stock fell 17% to $1.77 in premarket trading Wednesday. Through Tuesday's close, shares have lost nearly half of their value in the past year. \n\n\n  Ahead of the opening bell, the Irvine, Calif., biotech company said it will sell about 15.2 million shares of its common stock for $1.65 apiece. To certain investors, the company will instead sell pre-funded warrants immediately exercisable to purchase common stock. \n\n\n  Eledon will also grant underwriters a 30-day option to purchase up to about 4.55 million shares of common stock at a discounted price. \n\n\n  The company said it will use net proceeds from the sale to support the clinical development of its product candidates and advance its pipeline programs, as well as for general corporate purposes. \n\n\n  Leerink Partners, Cantor and LifeSci Capital are acting as joint book-running managers for the offering, which is expected to close on or about Thursday. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 12, 2025 08:45 ET (13:45 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}